Positive effect of pentoxifylline on medication-related osteonecrosis of the jaw

被引:0
|
作者
Li, J. [1 ]
Wang, W. [1 ]
机构
[1] Kunming Med Univ, Affiliated Stomatol Hosp, Dept Oral & Maxillofacial Surg, Kunming 650106, Yunnan, Peoples R China
关键词
Pentoxifylline (PTX); Bisphosphonates(BPs); Medication-related osteonecrosis of the jaw (MRONJ); TGF-beta; 1; Phosphorous necrosis of the jaw(PNJ); BISPHOSPHONATE-RELATED OSTEONECROSIS; PHOSPHODIESTERASE INHIBITOR; BONE REPAIR; EXPRESSION; TOCOPHEROL; DIFFERENTIATION; PERSPECTIVES; ZOLEDRONATE; ALENDRONATE; MANAGEMENT;
D O I
暂无
中图分类号
R78 [口腔科学];
学科分类号
1003 ;
摘要
The pathophysiology of medication-related osteonecrosis of the jaw (MRONJ) is associated with microcirculatory dysfunction, direct toxicity to osteoblast, osteoclast and bone marrow stromal cells (BMSCs), bacterial infection, related factors, immune dysfunction, and transforming growth factor-beta (TGF-beta 1) pathway. MRONJ and osteoradionecrosis of the jaw (ORN) shared some histological characteristics, suggesting that improving blood flow, increasing blood supply to the lesion and regulating TGF-beta 1/BMP signaling can improve osteonecrosis of the jaw, thus PTX as non-selective PEDs inhibit, which can significantly improve microcirculation of ORN and anti-fibrotic drugs, have also similar preventive and therapeutic effects on MRONJ. However, as to whether PTX can treat and prevent phosphorous necrosis of the jaw(PNJ) remains to be further studied. (C) 2019 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:264 / 267
页数:4
相关论文
共 50 条
  • [21] Bacterial diversity in medication-related osteonecrosis of the jaw
    Hallmer, Fredrik
    Bjornland, Tore
    Andersson, Gunilla
    Becktor, Jonas P.
    Kristoffersen, Anne K.
    Enersen, Morten
    ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY, 2017, 123 (04): : 436 - 444
  • [22] Medication-related osteonecrosis of the jaw - Personal comments
    Pitak-Arnnop, Poramate
    AMERICAN JOURNAL OF OTOLARYNGOLOGY, 2018, 39 (06) : 802 - 802
  • [23] Immune Dysfunction in Medication-Related Osteonecrosis of the Jaw
    Roato, Ilaria
    Mauceri, Rodolfo
    Notaro, Vincenzo
    Genova, Tullio
    Fusco, Vittorio
    Mussano, Federico
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (09)
  • [24] Prognostic factors of the medication-related osteonecrosis of the jaw
    Szentpeteri Szofia
    Restar Laszlo
    Nemeth Zsolt
    Vaszilko Mihaly
    ORVOSI HETILAP, 2020, 161 (08) : 283 - 289
  • [25] Bisphosphonate and Medication-Related Osteonecrosis of the Jaw: A Review
    Muecke, Thomas
    Krestan, Christian R.
    Mitchell, David A.
    Kirschke, Jan S.
    Wutzl, Arno
    SEMINARS IN MUSCULOSKELETAL RADIOLOGY, 2016, 20 (03) : 305 - 314
  • [26] Interventions for managing medication-related osteonecrosis of the jaw
    Beth-Tasdogan, Natalie H.
    Mayer, Benjamin
    Hussein, Heba
    Zolk, Oliver
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2017, (10):
  • [27] Medication-related osteonecrosis of the jaw: A literature review
    Kuroshima, Shinichiro
    Sasaki, Muneteru
    Sawase, Takashi
    JOURNAL OF ORAL BIOSCIENCES, 2019, 61 (02) : 99 - 104
  • [28] Necrotizing Fasciitis with Medication-related Osteonecrosis of the Jaw
    Ishibashi, Hiroki
    Sasahara, Teppei
    Katagiri, Oh
    Yamada, Tetsuhisa
    INTERNAL MEDICINE, 2024, 63 (06) : 887 - 888
  • [29] Diagnosis and Staging of Medication-Related Osteonecrosis of the Jaw
    Ruggiero, Salvatore L.
    ORAL AND MAXILLOFACIAL SURGERY CLINICS OF NORTH AMERICA, 2015, 27 (04) : 479 - +
  • [30] Interventions for managing medication-related osteonecrosis of the jaw
    Beth-Tasdogan, Natalie H.
    Mayer, Benjamin
    Hussein, Heba
    Zolk, Oliver
    Peter, Jens-Uwe
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2022, (07):